The Alliance NCI Community Oncology Research Program (NCORP) Research Base conducts interventional and observational clinical trials as well as database analyses addressing important questions concerning cancer prevention, screening, symptom intervention, post-treatment surveillance/survivorship, quality of life and cancer care delivery. We place special emphasis upon issues affecting minority, underserved and elderly patient groups, and upon building strong collegial relationships with NCORP Community sites and Minority/Underserved Community sites. The Alliance for Clinical Trials in Oncology (Alliance), one of the five National Clinical Trials Network (NCTN) groups, serves as the coordinating center for the conduct of all NCORP Research Base trials. The Alliance members represent community practices and academic medical centers in approximately equal number, so the results of the trials broadly reflect the actual experience of patients across the United States. In order to improve our understanding of the biological basis of cancer risk and pre-malignant disease, biomarkers that detect pre-symptomatic newly diagnosed or recurrent malignancies, as well as the physiologic mechanisms of cancer-related symptoms and treatment-related toxicities, most of our clinical trials include translational research questions requiring the collection of tumor tissue, premalignant tissue samples, blood, or other human biospecimens. These biospecimens create an invaluable repository for understanding the associations between laboratory and clinical observations. The Alliance NCORP Research Base collaborates broadly with other NCORP Research Bases to enroll patients in trials, conduct translational studies, and share data and biospecimens for pooled analyses. We also collaborate broadly with other NCI-funded investigators and consortia, as well as investigators supported through non-NCI sources. Results of Alliance investigator efforts have resulted in more than 99 abstracts and manuscripts over the past five years, many resulting in significant beneficial changes in clinical practice. The scientific questions answered by the Alliance NCORP Research Base represent meaningful and innovative contributions to biomedical sciences, and can only be addressed through a publicly-funded research network.
Approximately one in three women and one in two men in the United States will be diagnosed with cancer during their lifetime. Research to prevent cancer, detect cancer while it is still curable, improve symptoms related to cancer and its treatment, and enhance cancer care delivery strategies will provide major health and economic benefits for Americans and people around the world.
|Sio, Terence T; Atherton, Pamela J; Pederson, Levi D et al. (2018) Daily Lisinopril vs Placebo for Prevention of Chemoradiation-Induced Pulmonary Distress in Patients With Lung Cancer (Alliance MC1221): A Pilot Double-Blind Randomized Trial. Int J Radiat Oncol Biol Phys :|
|Tallarico, Michael; Foster, Jared C; Seisler, Drew et al. (2018) Frequency and impact of grade three or four toxicities of novel agents on outcomes of older patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma (alliance A151611). J Geriatr Oncol 9:321-328|
|Barton, Debra L; Sloan, Jeff A; Shuster, Lynne T et al. (2018) Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance). Support Care Cancer 26:643-650|
|Woyach, Jennifer A; Ruppert, Amy S; Heerema, Nyla A et al. (2018) Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. N Engl J Med 379:2517-2528|
|Feliciano, Josephine L; Le-Rademacher, Jennifer G; Gajra, Ajeet et al. (2018) Do older patients with non-small cell lung cancer also benefit from first-line platinum-based doublet chemotherapy? Observations from a pooled analysis of 730 prospectively-treated patients (Alliance Study A151622). J Geriatr Oncol 9:501-506|
|Pacyna, Joel E; Kim, Simon; Yost, Kathleen et al. (2018) The comparative effectiveness of decision aids in diverse populations with early stage prostate cancer: a study protocol for a cluster-randomized controlled trial in the NCI Community Oncology Research Program (NCORP), Alliance A191402CD. BMC Cancer 18:788|
|Morrison, Vicki A; McCall, Linda; Muss, Hyman B et al. (2018) The impact of actual body weight-based chemotherapy dosing and body size on adverse events and outcome in older patients with breast cancer: Results from Cancer and Leukemia Group B (CALGB) trial 49907 (Alliance A151436). J Geriatr Oncol 9:228-234|
|Freedman, Rachel A; Dockter, Travis J; Lafky, Jacqueline M et al. (2018) Promoting Accrual of Older Patients with Cancer to Clinical Trials: An Alliance for Clinical Trials in Oncology Member Survey (A171602). Oncologist 23:1016-1023|
|Li, Daneng; McCall, Linda M; Hahn, Olwen M et al. (2018) Identification of risk factors for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: a CALGB 40503 (alliance) correlative study. Breast Cancer Res Treat 171:325-334|
|Orchard, Tonya S; Andridge, Rebecca R; Yee, Lisa D et al. (2018) Diet Quality, Inflammation, and Quality of Life in Breast Cancer Survivors: A Cross-Sectional Analysis of Pilot Study Data. J Acad Nutr Diet 118:578-588.e1|
Showing the most recent 10 out of 101 publications